TR-701 FA

· Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc.

Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for TR-701 FA, covering 2015-03-12 to 2016-05-03. Get the full timeline:

Most recent: Clinical Trial Update: A Phase 1 TR-701 FA Study of Blood Pressure Response Post Tyramine Challenge [Phase 1]